MX337756B - Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo. - Google Patents

Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo.

Info

Publication number
MX337756B
MX337756B MX2011001883A MX2011001883A MX337756B MX 337756 B MX337756 B MX 337756B MX 2011001883 A MX2011001883 A MX 2011001883A MX 2011001883 A MX2011001883 A MX 2011001883A MX 337756 B MX337756 B MX 337756B
Authority
MX
Mexico
Prior art keywords
hig2
same
epitope peptide
vaccines containing
urlc10
Prior art date
Application number
MX2011001883A
Other languages
English (en)
Other versions
MX2011001883A (es
Inventor
Takuya Tsunoda
Ryuji Ohsawa
Sachiko Yoshimura
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of MX2011001883A publication Critical patent/MX2011001883A/es
Publication of MX337756B publication Critical patent/MX337756B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un agente o composición farmacéutica que contiene uno o más péptidos que tienen la secuencia de aminoácido de SEQ ID NO: 1 ó 2, uno o más polinucleótidos que codifican dicho péptido formulado para el tratamiento y/o prevención de cáncer en un sujeto cuyo antígeno HLA-A es HLA-A0206. Además, la presente invención proporciona un método para inducir CTL y células que presentan antígenos utilizando dichos péptidos, polinucleótidos o agentes farmacéuticos.
MX2011001883A 2008-08-19 2009-08-14 Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo. MX337756B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8997208P 2008-08-19 2008-08-19
PCT/JP2009/003897 WO2010021112A1 (en) 2008-08-19 2009-08-14 Hig2 and urlc10 epitope peptide and vaccines containing the same

Publications (2)

Publication Number Publication Date
MX2011001883A MX2011001883A (es) 2011-03-29
MX337756B true MX337756B (es) 2016-03-17

Family

ID=41707003

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011001883A MX337756B (es) 2008-08-19 2009-08-14 Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo.
MX2013010331A MX355054B (es) 2008-08-19 2009-08-14 Péptido de epítope hig2 y urlc10 y vacunas que contienen el mismo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013010331A MX355054B (es) 2008-08-19 2009-08-14 Péptido de epítope hig2 y urlc10 y vacunas que contienen el mismo.

Country Status (17)

Country Link
US (1) US9119800B2 (es)
EP (1) EP2328600B9 (es)
JP (1) JP5633025B2 (es)
KR (1) KR101713581B1 (es)
CN (2) CN102186491B (es)
AU (1) AU2009283763B2 (es)
BR (1) BRPI0917391A2 (es)
CA (1) CA2734467C (es)
DK (1) DK2328600T3 (es)
ES (1) ES2566011T3 (es)
HK (1) HK1157204A1 (es)
IL (1) IL211117A (es)
MX (2) MX337756B (es)
RU (1) RU2529373C2 (es)
SG (2) SG193806A1 (es)
TW (2) TWI580431B (es)
WO (1) WO2010021112A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI610939B (zh) * 2007-02-21 2018-01-11 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
DK2640842T3 (en) * 2010-11-17 2018-08-13 Aduro Biotech Inc Methods and compositions for inducing an immune response to EGFRVIII
JP6255594B2 (ja) 2012-07-10 2018-01-10 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＬＹ６Ｋエピトープペプチドおよびこれを含有するワクチン
BR112017002193A2 (pt) * 2014-08-04 2017-11-21 Oncotherapy Science Inc peptídeo derivado de urlc10 e vacina contendo o mesmo
RU2021127767A (ru) 2015-08-10 2021-11-23 Торэй Индастриз, Инк. Индуктор иммунитета
AU2016306527B2 (en) 2015-08-12 2022-03-17 Oncotherapy Science, Inc. DEPDC1-derived peptide and vaccine containing same
CA3059755A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
DK3538645T3 (da) 2017-06-20 2021-04-19 Inst Curie Immunceller der mangler suv39h1
CN115300609A (zh) * 2021-05-08 2022-11-08 西湖大学 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070014787A1 (en) 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
CA2381348C (en) * 1999-08-05 2009-10-06 Kyogo Itoh Lck-derived peptides activating ctls
AU7748200A (en) 1999-09-30 2001-04-30 Varian Associates, Inc. Hypoxia-related human genes, proteins, and uses thereof
WO2002030268A2 (en) 2000-10-13 2002-04-18 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
US20030232350A1 (en) 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20070015271A1 (en) 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CN1882698B (zh) * 2003-08-20 2011-05-25 肿瘤疗法科学股份有限公司 低氧可诱导的蛋白2(hig2)作为新的治疗肾细胞癌(rcc)的潜在标靶
EP1782827A4 (en) * 2004-06-21 2009-09-16 Greenpeptide Co Ltd PEPTIDE VACCINE FOR THE TREATMENT OF CANCER
CN101175862A (zh) 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 诊断膀胱癌的方法
ES2364670T3 (es) * 2005-02-25 2011-09-12 Oncotherapy Science, Inc. Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos ttk.
EP1854473A1 (en) 2005-03-03 2007-11-14 Takeda Pharmaceutical Company Limited Preventive/therapeutic agent for cancer
WO2007013575A2 (en) 2005-07-28 2007-02-01 Oncotherapy Science, Inc. Method for diagnosing and treating renal cell carcinoma
US20080306243A1 (en) 2005-09-07 2008-12-11 Nec Corporation Hla-Binding Peptide, and Dna Fragment and Recombinant Vector Coding for Said Hla-Binding Peptide
JP4840858B2 (ja) * 2006-03-16 2011-12-21 学校法人慶應義塾 癌ワクチン
CA2655361C (en) * 2006-06-16 2014-10-07 Kumamoto University Sparc-derived tumor rejection antigenic peptides and medicaments comprising the same
TWI610939B (zh) * 2007-02-21 2018-01-11 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
WO2009016691A1 (en) 2007-07-30 2009-02-05 Oncotherapy Science, Inc. Cancer associated gene ly6k
TW201000115A (en) 2008-06-11 2010-01-01 Oncotherapy Science Inc IQGAP3 epitope peptides and vaccines containing the same
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same

Also Published As

Publication number Publication date
JP5633025B2 (ja) 2014-12-03
TW201019952A (en) 2010-06-01
AU2009283763A1 (en) 2010-02-25
AU2009283763A2 (en) 2011-07-07
EP2328600A1 (en) 2011-06-08
MX355054B (es) 2018-04-03
WO2010021112A1 (en) 2010-02-25
IL211117A0 (en) 2011-04-28
EP2328600B1 (en) 2016-01-27
ES2566011T3 (es) 2016-04-08
AU2009283763B2 (en) 2014-06-19
US9119800B2 (en) 2015-09-01
DK2328600T3 (en) 2016-03-29
US20110243973A1 (en) 2011-10-06
EP2328600B9 (en) 2016-07-13
IL211117A (en) 2017-03-30
JP2012500184A (ja) 2012-01-05
BRPI0917391A2 (pt) 2015-12-01
CA2734467C (en) 2017-10-03
TWI543767B (zh) 2016-08-01
RU2011110376A (ru) 2012-09-27
KR101713581B1 (ko) 2017-03-08
HK1157204A1 (zh) 2012-06-29
SG10201610206VA (en) 2017-01-27
CA2734467A1 (en) 2010-02-25
CN102186491A (zh) 2011-09-14
MX2011001883A (es) 2011-03-29
CN104958753B (zh) 2018-09-25
SG193806A1 (en) 2013-10-30
EP2328600A4 (en) 2013-03-06
CN104958753A (zh) 2015-10-07
TW201500055A (zh) 2015-01-01
KR20110045052A (ko) 2011-05-03
RU2529373C2 (ru) 2014-09-27
CN102186491B (zh) 2015-06-10
TWI580431B (zh) 2017-05-01

Similar Documents

Publication Publication Date Title
MX355054B (es) Péptido de epítope hig2 y urlc10 y vacunas que contienen el mismo.
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EP3412304A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
NZ708990A (en) Method for activating helper t cell
EP3533461A3 (en) Prame derived peptides and immunogenic compositions comprising these
UA103751C2 (ru) Иммуногенный пептид для иммунотерапии
IN2014KN01715A (es)
NZ618391A (en) Antigenic tau peptides and uses thereof
WO2009025196A1 (ja) Foxm1ペプチドおよびこれを含む薬剤
NZ597858A (en) Vaccines and compositions against streptococcus pneumoniae
RU2013112616A (ru) Пептид cdca1 и включающее его фармацевтическое средство
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
MX2011008763A (es) Peptidos foxm1 y vacunas que contienen los mismos.
MX2011004176A (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo.
RU2009129531A (ru) Вакцины на основе пептида foxp3
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
WO2013171661A3 (en) Adjuvant formulations and methods
MY166516A (en) Tomm34 peptides and vaccines including the same
MX2011008917A (es) Peptidos vangl1 y vacunas que incluyen los mismos.
EP3868778A3 (en) Cdc45l peptides and vaccines including the same
GB201018125D0 (en) Peptide

Legal Events

Date Code Title Description
FG Grant or registration